Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Assertio Holdings, Inc.NASDAQ: ASRT

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $8.55M fell 49.9% year over year, behind the +26.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 6.1% from the prior quarter. Over 3 fiscal years it compounded at +51.7% a year.

Context

  • Cost of revenue amounted to 55.1% of revenue in FY2025, up 23.7 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -49.9% toward the trailing-twelve-month pace of +26.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.55M-6.1% QoQ
Last fiscal yearDec 2025
$65.39M+66.7% YoY
LTMMar 2026
$56.89M+26.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.9%——
1 year+66.7%——
3-year CAGR+51.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
65.39M USD
Year-over-year change
+66.7%
4-year CAGR
+42.6%

Cost of Revenue vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.1% is the highest of 7, against a peer median of -12.9%.
  • Cost of revenue amounts to 55.7% of revenue for ASRT, versus a peer median of 30.0%.
ASRT Competitors
Cost of Revenue for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCRInterCure Ltd.LTM Jun 2025₪202.51M ILS+4.0%+0.5%83.3%
ASRTAssertio Holdings, Inc.LTM Mar 2026$56.89M USD+26.1%+51.7%55.7%
FBIOFortress Biotech, Inc.LTM Mar 2026$23.48M USD+4.7%-12.1%35.5%
LUNGPulmonx CorporationLTM Mar 2026$21.7M USD-6.5%+19.2%24.5%
NTRBNutriband Inc.LTM Apr 2026$1.29M USD-19.4%+3.4%71.6%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$693K USD——7.6%
XBITXBiotech Inc.LTM Mar 2026$332K USD—+37.3%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$66K USD-82.3%——
VXRTVaxart, Inc.LTM Mar 2026$0 USD——0.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$228K USD-137.1%——
Peer median (excluding ASRT) —-12.9%+3.4%30.0%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue111.01M156.23M152.07M124.96M118.71M
Cost of Revenue15.83M18.75M27.02M39.23M65.39M
Gross Profit95.18M137.49M125.05M85.73M53.33M
Gross Margin85.7%88.0%82.2%68.6%44.9%
Research & Development002.84M3.82M1.69M
Selling, General & Admin56.56M48.1M69.74M76.95M68.86M
Operating Expenses85.76M98.08M368.59M110.21M70.55M
Depreciation & Amortization29.11M33.4M28.23M25.83M30.01M
EBITDA38.78M90.17M53.17M5.15M3.14M
EBITDA Margin34.9%57.7%35.0%4.1%2.6%
Operating Income9.42M39.41M(243.54M)(24.48M)(17.22M)
Operating Margin8.5%25.2%-160.1%-19.6%-14.5%
Interest Income0003.22M2.67M
Interest Expense10.22M7.96M3.38M3.04M3.08M
Other Income / Expenses(9.98M)(8.24M)(10.52M)2.95M(12.72M)
Income Before Tax(553K)31.17M(254.05M)(21.53M)(29.94M)
Pre-Tax Margin-0.5%19.9%-167.1%-17.2%-25.2%
Income Tax Expense728K(78.46M)77.89M52K435K
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Net Margin-1.2%70.2%-218.3%-17.3%-25.6%
EPS (Basic)(0.45)34.95(70.05)(3.45)(4.74)
EPS (Diluted)(0.45)30.45(70.05)(3.45)(4.74)
Weighted Avg Shares2.88M3.13M4.74M6.35M6.4M
Weighted Avg Shares (Diluted)2.88M3.64M4.74M6.35M6.4M

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.